Progressive Multifocal Leukoencephalopathy – Pipeline Review, 2024

Neurological disease continues to remain a global burden owing to the lack of proper treatment. Progressive Multifocal Leukoencephalopathy, is one such rare neurological disorder in which the cells responsible for the production of myelin are destroyed.  Myelin is essential for the central nervous system as it protects the nerve cells in the brain and spinal cord. It is caused by John Cunningham Virus (JCV), named after the patient in whom it was discovered. Symptoms of progressive multifocal leukoencephalopathy include lesions, loss of coordination, facial drooping, weakness, and others.

John Cunningham Virus (JCV) is found in up to 85% of the adult population and causes disease in multiple areas of the brain. According to the National Organization of Rare Disorders, 4,000 people every year develop progressive multifocal leukoencephalopathy in the U.S, and Europe combined. Current treatment for progressive multifocal leukoencephalopathy is the reversal or removal of source causing immunosuppression. This can be done through plasma exchange which enable the removal of agents that puts the patients at risk of developing progressive multifocal leukoencephalopathy.

Lack of effective therapy to block JCV without toxicity have encouraged many pharmaceutical and research institutes for conducting clinical study on progressive multifocal leukoencephalopathy. For instance; PyVST is a polyomavirus-specific T-Cells, which is being studied by the National Institute of Neurological Disorders and Stroke (NINDS) and is currently in phase 1 clinical trials for the treatment of progressive multifocal leukoencephalopathy.

At present around 43% of the pipeline candidates for Progressive Multifocal Leukoencephalopathy are in the phase 2 stage. More than half of the studies are sponsored by government research institutes.

To know how our report can help streamline your business, Speak to Analyst

Report Description

The report on ‘Progressive Multifocal Leukoencephalopathy – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Progressive Multifocal Leukoencephalopathy. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Progressive Multifocal Leukoencephalopathy.

The report on ‘Progressive Multifocal Leukoencephalopathy – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Progressive Multifocal Leukoencephalopathy
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Progressive Multifocal Leukoencephalopathy
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary